Author:
Quan Mo-Yuan,Song Xiu-Juan,Liu Hui-Jia,Deng Xiao-Hong,Hou Hui-Qing,Chen Li-Ping,Ma Tian-Zhao,Han Xu,He Xin-Xin,Jia Zhen,Guo Li
Funder
National Natural Science Foundation
Hebei Postgraduate Innovation project
Hebei critical medical science project
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Neurology,Immunology,General Neuroscience
Reference67 articles.
1. Jijin MJ, Rakaraddi M, Pai J, Jaishankar HP, Krupashankar R, Kavitha AP, et al. Low-level laser therapy versus 5% amlexanox: a comparison of treatment effects in a cohort of patients with minor aphthous ulcers. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121:269–73.
2. Imokawa S, Satou A, Taniguchi M, Toyoshima M, Nakazawa K, Hayakawa H, et al. Amlexanox has an acute bronchodilator effect in patients with aspirin-induced asthma (AIA). Nihon Kyobu Shikkan Gakkai Zasshi. 1993;31:976–82.
3. Oral EA, Reilly SM, Gomez AV, Meral R, Butz L, Ajluni N, et al. Inhibition of IKKvarepsilon and TBK1 improves glucose control in a subset of patients with type 2 diabetes. Cell Metab. 2017;26:157–70 e7.
4. Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180–90.
5. Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ, et al. An inhibitor of the protein kinases TBK1 and IKK-varepsilon improves obesity-related metabolic dysfunctions in mice. Nat Med. 2013;19:313–21.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献